Pre-clinical: RSV Vaccine
We have completed pre-clinical immunogenicity studies during 2016 and we plan to start protection studies with our Respiratory Syncytial Virus (RSV) vaccine candidate during 2017. Our RSV vaccine candidate will include proprietary immunogens, a proprietary self-assembling nanoparticle and a proven adjuvant.
There is currently no vaccine against RSV. Our RSV vaccine will initially be a substitute for a therapeutic antibody (Synagis®) with annual sales over $1 billion. The objective of our RSV vaccine is to prevent RSV infections in newborns, infants and elderly adults and to reduce the significant rates of bronchiolitis, pneumonia and death associated with RSV infections in these various populations.